Michael W Weiner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2463491/publications.pdf

Version: 2024-02-01

418 papers	49,946 citations	1099 112 h-index	2127 203 g-index
453 all docs	453 docs citations	453 times ranked	36001 citing authors

#	Article	IF	Citations
1	Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology, The, 2010, 9, 119-128.	10.2	3,792
2	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurology, The, 2013, 12, 207-216.	10.2	3,378
3	The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. Journal of Magnetic Resonance Imaging, 2008, 27, 685-691.	3.4	2,553
4	Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain, 2009, 132, 1355-1365.	7.6	975
5	Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). , 2005, 1, 55-66.		925
6	The Alzheimer's Disease Neuroimaging Initiative. Neuroimaging Clinics of North America, 2005, 15, 869-877.	1.0	863
7	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	27.8	772
8	The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging and Behavior, 2014, 8, 153-182.	2.1	696
9	Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiology of Aging, 2011, 32, 1207-1218.	3.1	611
10	Identification of common variants associated with human hippocampal and intracranial volumes. Nature Genetics, 2012, 44, 552-561.	21.4	594
11	A Network Diffusion Model of Disease Progression in Dementia. Neuron, 2012, 73, 1204-1215.	8.1	582
12	Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Annals of Neurology, 2012, 72, 578-586.	5.3	559
13	The Preclinical Alzheimer Cognitive Composite. JAMA Neurology, 2014, 71, 961.	9.0	548
14	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2013, 9, e111-94.	0.8	535
15	Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain, 2010, 133, 3336-3348.	7.6	455
16	The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans. Alzheimer's and Dementia, 2010, 6, 202.	0.8	443
17	Development and assessment of a composite score for memory in the Alzheimerâ€™s Disease Neuroimaging Initiative (ADNI). Brain Imaging and Behavior, 2012, 6, 502-516.	2.1	443
18	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2012, 8, S1-68.	0.8	432

#	Article	IF	Citations
19	Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans. Alzheimer's and Dementia, 2010, 6, 239-246.	0.8	402
20	Cascading network failure across the Alzheimerâ€™s disease spectrum. Brain, 2016, 139, 547-562.	7.6	401
21	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Annals of Neurology, 2016, 79, 929-939.	5.3	381
22	Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimer's and Dementia, 2010, 6, 265-273.	0.8	378
23	Plasma tau in Alzheimer disease. Neurology, 2016, 87, 1827-1835.	1.1	371
24	Metabolic network failures in Alzheimer's disease: A biochemical roadÂmap. Alzheimer's and Dementia, 2017, 13, 965-984.	0.8	362
25	Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurology, 2016, 73, 60.	9.0	354
26	Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiology of Aging, 2012, 33, 1203-1214.e2.	3.1	346
27	Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. NeuroImage, 2010, 53, 1051-1063.	4.2	340
28	Hippocampal Atrophy as a Quantitative Trait in a Genome-Wide Association Study Identifying Novel Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2009, 4, e6501.	2.5	321
29	Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: An MRI study of 676 AD, MCI, and normal subjects. NeuroImage, 2008, 43, 458-469.	4.2	317
30	Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2010, 6, 212-220.	0.8	311
31	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA - Journal of the American Medical Association, 2017, 317, 2305.	7.4	311
32	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2019, 15, 106-152.	0.8	302
33	Smoking and increased Alzheimer's disease risk: A review of potentialÂmechanisms. Alzheimer's and Dementia, 2014, 10, S122-45.	0.8	285
34	Neuropathological basis of magnetic resonance images in aging and dementia. Annals of Neurology, 2008, 63, 72-80.	5.3	282
35	Effectiveness of regional DTI measures in distinguishing Alzheimer's disease, MCI, and normal aging. NeuroImage: Clinical, 2013, 3, 180-195.	2.7	277
36	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimer's and Dementia, 2017, 13, 561-571.	0.8	266

#	Article	IF	Citations
37	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: AÂreview of papers published since its inception. Alzheimer's and Dementia, 2015, 11, e1-120.	0.8	261
38	Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). NeuroImage, 2009, 45, 1107-1116.	4.2	258
39	Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimer's and Dementia, 2010, 6, 230-238.	0.8	256
40	Early increase of CSF sTREM2 in Alzheimerâ€™s disease is associated with tau related-neurodegeneration but not with amyloid-Î² pathology. Molecular Neurodegeneration, 2019, 14, 1.	10.8	253
41	The future of bloodâ€based biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 115-131.	0.8	250
42	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	12.8	250
43	Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. Alzheimer's and Dementia, 2015, 11, 792-814.	0.8	241
44	Magnetic Resonance Imaging of Hippocampal Subfields in Posttraumatic Stress Disorder. Archives of General Psychiatry, 2010, 67, 296.	12.3	239
45	Voxelwise genome-wide association study (vGWAS). NeuroImage, 2010, 53, 1160-1174.	4.2	239
46	Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurology, 2016, 73, 721.	9.0	235
47	Decreased hippocampal N-acetylaspartate in the absence of atrophy in posttraumatic stress disorder. Biological Psychiatry, 2001, 50, 952-959.	1.3	231
48	Longitudinal MRI atrophy biomarkers: Relationship to conversion in the ADNI cohort. Neurobiology of Aging, 2010, 31, 1401-1418.	3.1	230
49	A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8404-8409.	7.1	227
50	Nearly automatic segmentation of hippocampal subfields in in vivo focal T2-weighted MRI. NeuroImage, 2010, 53, 1208-1224.	4.2	222
51	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Molecular Medicine, 2016, 8, 1184-1196.	6.9	219
52	Longitudinal Changes in White Matter Disease and Cognition in the First Year of the Alzheimer Disease Neuroimaging Initiative. Archives of Neurology, 2010, 67, 1370.	4.5	216
53	Mild cognitive impairment due to Alzheimer disease in the community. Annals of Neurology, 2013, 74, 199-208.	5.3	215
54	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	14.8	213

#	Article	IF	Citations
55	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimer's and Dementia, 2017, 13, e1-e85.	0.8	213
56	Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. NeuroImage, 2009, 45, S3-S15.	4.2	211
57	Neuron loss localizes human temporal lobe epilepsy by in vivo proton magnetic resonance spectroscopic imaging. Annals of Neurology, 1993, 34, 788-794.	5.3	207
58	Guidelines for the standardization of preanalytic variables for bloodâ€based biomarker studies in Alzheimer's disease research. Alzheimer's and Dementia, 2015, 11, 549-560.	0.8	205
59	Independent information from cerebrospinal fluid amyloid-Î² and florbetapir imaging in Alzheimer's disease. Brain, 2015, 138, 772-783.	7.6	200
60	Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimerâ€™s disease. Brain, 2015, 138, 3373-3385.	7.6	200
61	Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia. Journal of Magnetic Resonance Imaging, 2002, 16, 305-310.	3.4	198
62	Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. NeuroImage, 2006, 31, 627-640.	4.2	198
63	Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. Alzheimer's and Dementia, 2019, 15, 232-244.	0.8	198
64	Evidence for Ordering of Alzheimer Disease Biomarkers. Archives of Neurology, 2011, 68, 1526.	4.5	195
65	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	21.4	192
66	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimerâ€™s Disease Neuroimaging Initiative. Molecular Psychiatry, 2021, 26, 429-442.	7.9	186
67	Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. NeuroImage, 2008, 43, 59-68.	4.2	181
68	Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiology of Aging, 2010, 31, 1463-1480.	3.1	181
69	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's and Dementia, 2015, 11, 865-884.	0.8	181
70	Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Human Brain Mapping, 2009, 30, 2766-2788.	3.6	178
71	Network Diffusion Model of Progression Predicts Longitudinal Patterns of Atrophy and Metabolism in Alzheimerâ€™s Disease. Cell Reports, 2015, 10, 359-369.	6.4	177
72	Standardization of analysis sets for reporting results from ADNI MRI data. Alzheimer's and Dementia, 2013, 9, 332-337.	0.8	172

#	Article	IF	Citations
73	Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiology of Aging, 2010, 31, 1326-1339.	3.1	170
74	Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiology of Aging, 2010, 31, 1429-1442.	3.1	165
75	Breakdown of Brain Connectivity Between Normal Aging and Alzheimer's Disease: A Structuralk-Core Network Analysis. Brain Connectivity, 2013, 3, 407-422.	1.7	162
76	The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. Alzheimer's and Dementia, 2015, 11, 111-125.	0.8	162
77	Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging and Behavior, 2014, 8, 183-207.	2.1	161
78	Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Annals of Neurology, 2010, 67, 308-316.	5.3	160
79	Alzheimer's Disease Neuroimaging Initiative: A one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. NeuroImage, 2009, 45, 645-655.	4.2	159
80	APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimer's and Dementia, 2015, 11, 1417-1429.	0.8	157
81	Longitudinal Change of Biomarkers in Cognitive Decline. Archives of Neurology, 2011, 68, 1257.	4.5	152
82	Factors affecting AÎ² plasma levels and their utility as biomarkers in ADNI. Acta Neuropathologica, 2011, 122, 401-13.	7.7	151
83	Association of brain amyloid-Î² with cerebral perfusion and structure in Alzheimerâ€™s disease and mild cognitive impairment. Brain, 2014, 137, 1550-1561.	7.6	150
84	3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. NeuroImage, 2008, 41, 19-34.	4.2	149
85	Estimating longâ€term multivariate progression from shortâ€term data. Alzheimer's and Dementia, 2014, 10, S400-10.	0.8	148
86	Evidence of an abnormal intramuscular component of fatigue in multiple sclerosis. Muscle and Nerve, 1995, 18, 1403-1411.	2.2	146
87	Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative. NeuroImage, 2010, 51, 654-664.	4.2	145
88	Characterizing Alzheimer's disease using a hypometabolic convergence index. NeuroImage, 2011, 56, 52-60.	4.2	144
89	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimer's and Dementia, 2015, 11, 740-756.	0.8	142
90	Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. JAMA Network Open, 2019, 2, e197978.	5.9	142

#	Article	IF	Citations
91	Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer's disease. NeuroImage, 2010, 51, 542-554.	4.2	141
92	Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4768-4773.	7.1	141
93	Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Brain, 2014, 137, 3047-3060.	7.6	140
94	Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathologica Communications, 2013, 1, 65.	5.2	138
95	Developing novel bloodâ€based biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 109-114.	0.8	138
96	Depressive Symptoms in Mild Cognitive Impairment Predict Greater Atrophy in Alzheimer's Disease-Related Regions. Biological Psychiatry, 2012, 71, 814-821.	1.3	135
97	Measurement of MRI scanner performance with the ADNI phantom. Medical Physics, 2009, 36, 2193-2205.	3.0	134
98	Removal of lipid artifacts in1H spectroscopic imaging by data extrapolation. Magnetic Resonance in Medicine, 1996, 35, 678-687.	3.0	133
99	Presurgical multimodality neuroimaging in electroencephalographic lateralized temporal lobe epilepsy. Annals of Neurology, 1997, 42, 829-837.	5.3	133
100	Treatment With Cholinesterase Inhibitors and Memantine of Patients in the Alzheimer's Disease Neuroimaging Initiative. Archives of Neurology, 2011, 68, 58.	4.5	133
101	Proton magnetic resonance spectroscopy of human brain: Applications to normal white matter, chronic infarction, and MRI white matter signal hyperintensities. Magnetic Resonance in Medicine, 1992, 26, 313-327.	3.0	131
102	Locally linear embedding (LLE) for MRI based Alzheimer's disease classification. NeuroImage, 2013, 83, 148-157.	4.2	131
103	Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjects. NeuroImage, 2009, 48, 668-681.	4.2	129
104	Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils. NeuroImage, 2008, 39, 1752-1762.	4.2	128
105	3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiology of Aging, 2010, 31, 1284-1303.	3.1	127
106	The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Frontiers in Aging Neuroscience, 2013, 5, 11.	3.4	126
107	Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection. NeuroImage, 2010, 50, 516-523.	4.2	125
108	Rich club analysis in the Alzheimer's disease connectome reveals a relatively undisturbed structural core network. Human Brain Mapping, 2015, 36, 3087-3103.	3.6	125

#	Article	IF	Citations
109	Improved Power for Characterizing Longitudinal Amyloid-Î² PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region. Journal of Nuclear Medicine, 2015, 56, 560-566.	5.0	122
110	AddNeuroMed and ADNI: Similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. NeuroImage, 2011, 58, 818-828.	4.2	121
111	N-Acetylaspartate as an in vivo Marker of Neuronal Viability in Kainate-Induced Status Epilepticus: 1H Magnetic Resonance Spectroscopic Imaging. Journal of Cerebral Blood Flow and Metabolism, 1994, 14, 373-382.	4.3	120
112	Postexercise phosphocreatine resynthesis is slowed in multiple sclerosis. Muscle and Nerve, 1994, 17, 835-841.	2.2	119
113	Neuropsychological functioning in posttraumatic stress disorder and alcohol abuse.. Neuropsychology, 2006, 20, 716-726.	1.3	118
114	Hippocampal Volume Differences in Gulf War Veterans with Current Versus Lifetime Posttraumatic Stress Disorder Symptoms. Biological Psychiatry, 2011, 69, 541-548.	1.3	118
115	Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain, 2011, 134, 1479-1492.	7.6	118
116	GWAS of longitudinal amyloid accumulation on¹⁸F-florbetapir PET in Alzheimerâ€™s disease implicates microglial activation geneIL1RAP. Brain, 2015, 138, 3076-3088.	7.6	117
117	Voxelwise gene-wide association study (vGeneWAS): Multivariate gene-based association testing in 731 elderly subjects. NeuroImage, 2011, 56, 1875-1891.	4.2	116
118	Whole-brain analysis reveals increased neuroanatomical asymmetries in dementia for hippocampus and amygdala. Brain, 2016, 139, 3253-3266.	7.6	116
119	Left frontal cortex connectivity underlies cognitive reserve in prodromal Alzheimer disease. Neurology, 2017, 88, 1054-1061.	1.1	116
120	Applying human factors principles to alert design increases efficiency and reduces prescribing errors in a scenario-based simulation. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, e287-e296.	4.4	115
121	Sex and APOE Îµ4 genotype modify the Alzheimerâ€™s disease serum metabolome. Nature Communications, 2020, 11, 1148.	12.8	115
122	Effects of exercise on muscle activation and metabolism in multiple sclerosis. Muscle and Nerve, 1994, 17, 1162-1169.	2.2	113
123	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1111.	9.0	112
124	Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease. Neurology, 2013, 80, 1194-1201.	1.1	111
125	Unbiased tensor-based morphometry: Improved robustness and sample size estimates for Alzheimer's disease clinical trials. NeuroImage, 2013, 66, 648-661.	4.2	103
126	Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. NeuroImage, 2009, 46, 394-410.	4.2	102

#	Article	IF	Citations
127	Association between mitochondrial DNA variations and Alzheimer's disease in the ADNI cohort. Neurobiology of Aging, 2010, 31, 1355-1363.	3.1	97
128	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Annals of Clinical and Translational Neurology, 2014, 1, 534-543.	3.7	96
129	Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology, 2019, 93, e322-e333.	1.1	96
130	Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiology of Aging, 2010, 31, 1340-1354.	3.1	95
131	Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. NeuroImage: Clinical, 2014, 4, 45-52.	2.7	93
132	Association between tau deposition and antecedent amyloid-Î² accumulation rates in normal and early symptomatic individuals. Brain, 2017, 140, 1499-1512.	7.6	93
133	Automated MRI measures predict progression to Alzheimer's disease. Neurobiology of Aging, 2010, 31, 1364-1374.	3.1	91
134	Discovery and replication of gene influences on brain structure using LASSO regression. Frontiers in Neuroscience, 2012, 6, 115.	2.8	91
135	The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions. Alzheimer's and Dementia, 2016, 12, 1113-1115.	0.8	91
136	The Brain Health Registry: An internetâ€based platform for recruitment, assessment, and longitudinal monitoring of participants for neuroscience studies. Alzheimer's and Dementia, 2018, 14, 1063-1076.	0.8	91
137	Alzheimer's Disease Under Managed Care: Implications from Medicare Utilization and Expenditure Patterns. Journal of the American Geriatrics Society, 1998, 46, 762-770.	2.6	90
138	Synergistic Effects of Ischemia and Î²-Amyloid Burden on Cognitive Decline in Patients With Subcortical Vascular Mild Cognitive Impairment. JAMA Psychiatry, 2014, 71, 412.	11.0	90
139	Validation of Plasma Amyloid-Î² 42/40 for Detecting Alzheimer Disease Amyloid Plaques. Neurology, 2022, 98, .	1.1	89
140	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 Î²-Amyloid Measures Across the Spectrum of Alzheimer Disease. JAMA Neurology, 2015, 72, 571.	9.0	87
141	Abnormal N-acetylaspartate in hippocampus and anterior cingulate in posttraumatic stress disorder. Psychiatry Research - Neuroimaging, 2008, 162, 147-157.	1.8	85
142	Transforming cerebrospinal fluid AÎ²42 measures into calculated Pittsburgh compound B units of brain AÎ² amyloid. , 2011, 7, 133-141.		85
143	Worldwide Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2012, 8, 337-342.	0.8	84
144	Functional significance of upper and lower motor neuron impairment in amyotrophic lateral sclerosis. , 1998, 21, 762-768.		83

#	Article	IF	Citations
145	Vascular risk and AÎ² interact to reduce cortical thickness in AD vulnerable brain regions. Neurology, 2014, 83, 40-47.	1.1	83
146	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimerâ€™s disease. Brain, 2018, 141, 1186-1200.	7.6	83
147	Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. Alzheimer's and Dementia, 2018, 14, 1077-1087.	0.8	83
148	Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. Alzheimer's and Dementia, 2015, 11, 734-739.	0.8	80
149	Increased pH and Seizure Foci Inorganic Phosphate in Temporal Demonstrated by [31P]MRS. Epilepsia, 1992, 33, 618-623.	5.1	79
150	Mapping Alzheimer's disease progression in 1309 MRI scans: Power estimates for different inter-scan intervals. NeuroImage, 2010, 51, 63-75.	4.2	79
151	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimer's and Dementia, 2015, 11, 772-791.	0.8	79
152	Diffusion MRI Indices and Their Relation to Cognitive Impairment in Brain Aging: The Updated Multi-protocol Approach in ADNI3. Frontiers in Neuroinformatics, 2019, 13, 2.	2.5	79
153	Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. NeuroImage, 2010, 51, 488-499.	4.2	78
154	HippocampalN-acetylaspartate in neocortical epilepsy and mesial temporal lobe epilepsy. Annals of Neurology, 1997, 42, 194-199.	5.3	77
155	Accurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry. NeuroImage, 2011, 57, 5-14.	4.2	77
156	Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathologica Communications, 2014, 2, 26.	5.2	77
157	Military Risk Factors for Cognitive Decline, Dementia and Alzheimerâ€™s Disease. Current Alzheimer Research, 2013, 10, 907-930.	1.4	77
158	Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 645-653.	0.8	72
159	Cortisol, cytokines, and hippocampal volume interactions in the elderly. Frontiers in Aging Neuroscience, 2014, 6, 153.	3.4	70
160	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2017, 60, 92-103.	3.1	70
161	Medial temporal lobe subregional morphometry using high resolution MRI in Alzheimer's disease. Neurobiology of Aging, 2017, 49, 204-213.	3.1	70
162	Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiology of Aging, 2012, 33, 845-855.	3.1	68

#	Article	IF	Citations
163	Widespread white matter degeneration preceding the onset of dementia. Alzheimer's and Dementia, 2015, 11, 485.	0.8	67
164	Dissociation of [H+] from fatigue in human muscle detected by high time resolution31P-NMR. Muscle and Nerve, 1993, 16, 91-98.	2.2	66
165	Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensorâ€based morphometry. Human Brain Mapping, 2010, 31, 499-514.	3.6	66
166	Proton magnetic resonance spectroscopic imaging in patients with frontal lobe epilepsy. Annals of Neurology, 1995, 37, 279-281.	5.3	65
167	Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 177-188.	3.7	64
168	<scp>CSF</scp> progranulin increases in the course of Alzheimer's disease and is associated with <scp>sTREM</scp> 2, neurodegeneration and cognitive decline. EMBO Molecular Medicine, 2018, 10, .	6.9	64
169	Polygenic hazard score, amyloid deposition and Alzheimerâ€™s neurodegeneration. Brain, 2019, 142, 460-470.	7.6	63
170	Serum triglycerides in Alzheimer disease. Neurology, 2020, 94, e2088-e2098.	1.1	63
171	Prevention trials in Alzheimer's disease: An EU-US task force report. Progress in Neurobiology, 2011, 95, 594-600.	5.7	62
172	Effects of Chronic Alcohol Abuse and HIV Infection on Brain Phosphorus Metabolites. Alcoholism: Clinical and Experimental Research, 1995, 19, 685-692.	2.4	61
173	Diffusion weighted imaging-based maximum density path analysis and classification of Alzheimer's disease. Neurobiology of Aging, 2015, 36, S132-S140.	3.1	61
174	Amyloid burden, cerebrovascular disease, brain atrophy, and cognition in cognitively impaired patients. Alzheimer's and Dementia, 2015, 11, 494.	0.8	61
175	CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathologica, 2014, 127, 621-632.	7.7	60
176	Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2015, 11, 730-733.	0.8	60
177	Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia. American Journal of Geriatric Psychiatry, 2016, 24, 126-135.	1.2	60
178	Maximizing power to track Alzheimer's disease and MCI progression by LDA-based weighting of longitudinal ventricular surface features. NeuroImage, 2013, 70, 386-401.	4.2	59
179	Focal hemosiderin deposits and Î²â€amyloid load in the ADNI cohort. Alzheimer's and Dementia, 2013, 9, S116-23.	0.8	59
180	Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology. NeuroImage: Clinical, 2014, 4, 508-516.	2.7	59

#	Article	IF	Citations
181	Genome-wide pathway analysis of memory impairment in the Alzheimerâ€™s Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. Brain Imaging and Behavior, 2012, 6, 634-648.	2.1	58
182	Brain atrophy in HIV infection is more strongly associated with CDC clinical stage than with cognitive impairment. Journal of the International Neuropsychological Society, 1997, 3, 276-287.	1.8	56
183	Systematic comparison of different techniques to measure hippocampal subfield volumes in ADNI2. NeuroImage: Clinical, 2018, 17, 1006-1018.	2.7	56
184	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 824-857.	0.8	56
185	AÎ² Imaging: feasible, pertinent, and vital to progress in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 209-219.	6.4	55
186	Neural substrates of socioemotional selfâ€awareness in neurodegenerative disease. Brain and Behavior, 2014, 4, 201-214.	2.2	55
187	Non-invasive quantitation of human liver metabolites using image-guided31p magnetic resonance spectroscopy. NMR in Biomedicine, 1990, 3, 17-22.	2.8	54
188	Comparison of phantom and registration scaling corrections using the ADNI cohort. NeuroImage, 2009, 47, 1506-1513.	4.2	54
189	Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 1245-1254.	2.6	54
190	Traumatic brain injury may not increase the risk of Alzheimer disease. Neurology, 2017, 89, 1923-1925.	1.1	54
191	Unsupervised online neuropsychological test performance for individuals with mild cognitive impairment and dementia: Results from the Brain Health Registry. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 573-582.	2.4	54
192	Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline. Neurobiology of Aging, 2010, 31, 1386-1400.	3.1	53
193	Identifying Neuroimaging and Proteomic Biomarkers for MCI and AD via the Elastic Net. Lecture Notes in Computer Science, 2011, 7012, 27-34.	1.3	53
194	Correlation of early reduction in the apparent diffusion coefficient of water with blood flow reduction during middle cerebral artery occlusion in rats. Magnetic Resonance in Medicine, 1995, 34, 368-377.	3.0	52
195	Homocysteine effects on brain volumes mapped in 732 elderly individuals. NeuroReport, 2011, 22, 391-395.	1.2	52
196	Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1599-1608.	3.1	52
197	Failure to detect an association between selfâ€reported traumatic brain injury and Alzheimer's disease neuropathology and dementia. Alzheimer's and Dementia, 2019, 15, 686-698.	0.8	52
198	Genomic Copy Number Analysis in Alzheimer's Disease and Mild Cognitive Impairment: An ADNI Study. International Journal of Alzheimer's Disease, 2011, 2011, 1-10.	2.0	51

#	Article	IF	Citations
199	Emerging Î²-Amyloid Pathology and Accelerated Cortical Atrophy. JAMA Neurology, 2014, 71, 725.	9.0	51
200	Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2014, 10, S226-35.	0.8	51
201	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimerâ€™s disease. PLoS ONE, 2018, 13, e0195838.	2.5	51
202	Detection of Î²-amyloid positivity in Alzheimerâ€™s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Communications, 2021, 3, fcab008.	3.3	51
203	Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3985-3990.	7.1	50
204	Cerebral Amyloid and Hypertension are Independently Associated with White Matter Lesions in Elderly. Frontiers in Aging Neuroscience, 2015, 7, 221.	3.4	50
205	Brain Amyloid-Î² Burden Is Associated with Disruption of Intrinsic Functional Connectivity within the Medial Temporal Lobe in Cognitively Normal Elderly. Journal of Neuroscience, 2015, 35, 3240-3247.	3.6	50
206	Influence of Genetic Variation on Plasma Protein Levels in Older Adults Using a Multi-Analyte Panel. PLoS ONE, 2013, 8, e70269.	2.5	50
207	Assessing risk for preclinical Î²â€amyloid pathology with APOE, cognitive, and demographic information. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 76-84.	2.4	49
208	Tractâ€specific white matter hyperintensities disrupt neural network function in Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 225-235.	0.8	49
209	Detection of Exchange Reactions Involving Small Metabolite Pools Using NMR Magnetization Transfer Techniques: Relevance to Subcellular Compartmentation of Creatine Kinase. Magnetic Resonance in Medicine, 1985, 2, 586-594.	3.0	48
210	Protective variant for hippocampal atrophy identified by whole exome sequencing. Annals of Neurology, 2015, 77, 547-552.	5.3	48
211	Amyloid pathway-based candidate gene analysis of [11C]PiB-PET in the Alzheimerâ€™s Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging and Behavior, 2012, 6, 1-15.	2.1	47
212	Metabolic response of the human heart to inotropic stimulation:In vivo phosphorus-31 studies of normal and cardiomyopathic myocardium. Magnetic Resonance in Medicine, 1992, 25, 260-272.	3.0	46
213	Phosphorus magnetic resonance spectroscopic imaging in patients with frontal lobe epilepsy. Annals of Neurology, 1994, 35, 217-221.	5.3	45
214	The Effect of Subsyndromal Symptoms of Depression and White Matter Lesions on Disability for Individuals with Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2013, 21, 906-914.	1.2	45
215	ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease. NeuroImage: Clinical, 2014, 4, 461-472.	2.7	45
216	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimerâ€™s Disease: Results from the DIAN Study Group. PLoS ONE, 2016, 11, e0152082.	2.5	45

#	Article	IF	Citations
217	Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1197-1206.	0.8	45
218	Comparison of kâ€space sampling schemes for multidimensional MR spectroscopic imaging. Magnetic Resonance in Medicine, 1996, 36, 469-473.	3.0	44
219	Thickness network features for prognostic applications in dementia. Neurobiology of Aging, 2015, 36, S91-S102.	3.1	44
220	Brain structure and function as mediators of the effects of amyloid on memory. Neurology, 2015, 84, 1136-1144.	1.1	44
221	Fat-mass-related hormone, plasma leptin, predicts brain volumes in the elderly. NeuroReport, 2013, 24, 58-62.	1.2	43
222	Association of plasma and cortical amyloid beta is modulated by APOE Îµ4 status. Alzheimer's and Dementia, 2014, 10, e9-e18.	0.8	43
223	The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update. Alzheimer's and Dementia, 2015, 11, 850-859.	0.8	43
224	Accelerated functional brain aging in pre-clinical familial Alzheimerâ€™s disease. Nature Communications, 2021, 12, 5346.	12.8	43
225	Method to correlate1H MRSI and18FDG-PET. Magnetic Resonance in Medicine, 2000, 43, 244-250.	3.0	42
226	Identifying Cognitively Healthy Elderly Individuals with Subsequent Memory Decline by Using Automated MR Temporoparietal Volumes. Radiology, 2011, 259, 844-851.	7.3	42
227	Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiology of Aging, 2014, 35, 614-622.	3.1	42
228	Memory, executive, and multidomain subtle cognitive impairment. Neurology, 2015, 85, 144-153.	1.1	42
229	Predicting Reduction of Cerebrospinal Fluid Î²-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurology, 2015, 72, 554.	9.0	42
230	Accelerating rates of cognitive decline and imaging markers associated with Î²-amyloid pathology. Neurology, 2016, 86, 1887-1896.	1.1	42
231	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: AÂserial magnetic resonance imaging study. Alzheimer's and Dementia, 2018, 14, 43-53.	0.8	42
232	Late-Life Depression Is Associated With Reduced Cortical Amyloid Burden: Findings From the Alzheimerâ€™s Disease Neuroimaging Initiative Depression Project. Biological Psychiatry, 2021, 89, 757-765.	1.3	41
233	Alzheimer's disease disrupts rich club organization in brain connectivity networks. , 2013, , 266-269.		40
234	The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. , 2008, 4, 255-264.		39

#	Article	IF	Citations
235	Associations between Subjective Sleep Quality and Brain Volume in Gulf War Veterans. Sleep, 2014, 37, 445-452.	1.1	39
236	MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials. Neurobiology of Aging, 2016, 37, 26-37.	3.1	39
237	Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease. NeuroImage, 2015, 113, 61-69.	4.2	38
238	A deep learning framework identifies dimensional representations of Alzheimerâ€™s Disease from brain structure. Nature Communications, 2021, 12, 7065.	12.8	38
239	Neuroimaging predictors of brain amyloidosis in mild cognitive impairment. Annals of Neurology, 2013, 74, 188-198.	5.3	37
240	The transitional association between Î²â€amyloid pathology and regional brain atrophy. Alzheimer's and Dementia, 2015, 11, 1171-1179.	0.8	37
241	Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau. Brain Communications, 2020, 2, fcaa025.	3.3	37
242	Late contributions of repetitive head impacts and TBI to depression symptoms and cognition. Neurology, 2020, 95, e793-e804.	1.1	37
243	APOE-epsilon4 and aging of medial temporal lobe gray matter in healthy adults older than 50 years. Neurobiology of Aging, 2014, 35, 2479-2485.	3.1	36
244	Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures. Neurology, 2015, 84, 729-737.	1.1	36
245	Measuring longitudinal change in the hippocampal formation from in vivo high-resolution T2-weighted MRI. NeuroImage, 2012, 60, 1266-1279.	4.2	35
246	Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-Î²-Positive Subjects in the Alzheimer's Disease Continuum. Neurodegenerative Diseases, 2016, 16, 87-94.	1.4	35
247	White Matter Hyperintensities are associated with Amyloid Burden in APOE4 Non-Carriers. Journal of Alzheimer's Disease, 2014, 40, 877-886.	2.6	34
248	Evidence of Multiple Ethanol Pools in the Brain: An in Vivo Proton Magnetization Transfer Study. Alcoholism: Clinical and Experimental Research, 1996, 20, 1283-1288.	2.4	33
249	PBMC telomerase activity, but not leukocyte telomere length, correlates with hippocampal volume in major depression. Psychiatry Research - Neuroimaging, 2015, 232, 58-64.	1.8	33
250	Genome-wide association study identifies MAPT locus influencing human plasma tau levels. Neurology, 2017, 88, 669-676.	1.1	33
251	Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2015, 2, 534-547.	3.7	32
252	Mapping ventricular expansion onto cortical gray matter in older adults. Neurobiology of Aging, 2015, 36, S32-S41.	3.1	32

#	Article	IF	Citations
253	Cerebral amyloid is associated with greater white-matter hyperintensity accrual in cognitively normal older adults. Neurobiology of Aging, 2016, 48, 48-52.	3.1	32
254	TADPOLE Challenge: Accurate Alzheimerâ€™s Disease Prediction Through Crowdsourced Forecasting of Future Data. Lecture Notes in Computer Science, 2019, 11843, 1-10.	1.3	32
255	Regional Distribution of Interictal 31P Metabolic Changes in Patients with Temporal Lobe Epilepsy. Epilepsia, 1998, 39, 527-536.	5.1	31
256	Connectivity network measures predict volumetric atrophy in mild cognitive impairment. Neurobiology of Aging, 2015, 36, S113-S120.	3.1	31
257	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. Neurobiology of Disease, 2020, 142, 104960.	4.4	31
258	Clinical magnetic resonance spectroscopy of brain, heart, liver, kidney, and cancer. A quantitative approach. NMR in Biomedicine, 1989, 2, 290-297.	2.8	30
259	Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiology of Aging, 2015, 36, 273-282.	3.1	30
260	Interaction of Cigarette Smoking History WithAPOEGenotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders. Nicotine and Tobacco Research, 2016, 18, 204-211.	2.6	30
261	The Relationship Between Gulf War Illness, BrainN-acetylaspartate, and Post-Traumatic Stress Disorder. Military Medicine, 2011, 176, 896-902.	0.8	29
262	Multimodal <scp>MRI</scp> â€based imputation of the A Î² + in early mild cognitive impairment. Annals of Clinical and Translational Neurology, 2014, 1, 160-170.	3.7	29
263	Low Plasma ApoE Levels Are Associated with Smaller Hippocampal Size in the Alzheimer's Disease Neuroimaging Initiative Cohort. Dementia and Geriatric Cognitive Disorders, 2015, 39, 154-166.	1.5	29
264	Online study partnerâ€reported cognitive decline in the Brain Health Registry. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 565-574.	3.7	29
265	KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimerâ€™s disease. Nature Communications, 2021, 12, 3825.	12.8	29
266	Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease. , 2011, 7, 425-435.		28
267	A commonly carried genetic variant in the delta opioid receptor gene, OPRD1, is associated with smaller regional brain volumes: Replication in elderly and young populations. Human Brain Mapping, 2014, 35, 1226-1236.	3.6	28
268	Cognitive and functional changes associated with AÎ² pathology and the progression to mild cognitive impairment. Neurobiology of Aging, 2016, 48, 172-181.	3.1	28
269	Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimerâ€™s disease. BMC Medical Genomics, 2017, 10, 29.	1.5	28
270	Dysregulated Fc gamma receptorâ€“mediated phagocytosis pathway in Alzheimer's disease: network-based gene expression analysis. Neurobiology of Aging, 2020, 88, 24-32.	3.1	28

#	Article	IF	Citations
271	Further insights into Alzheimer disease pathogenesis. Nature Reviews Neurology, 2013, 9, 65-66.	10.1	27
272	Cerebrospinal Fluid Î±-Synuclein and Lewy Body-Like Symptoms in Normal Controls, Mild Cognitive Impairment, and Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1007-1016.	2.6	27
273	Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer's disease clinical trial cohort. Alzheimer's and Dementia, 2016, 12, 977-986.	0.8	27
274	Amyloid pathology in the progression to mild cognitive impairment. Neurobiology of Aging, 2018, 64, 76-84.	3.1	27
275	Longitudinal effects of PTSD on memory functioning. Journal of the International Neuropsychological Society, 2009, 15, 853-861.	1.8	26
276	Genome-wide association identifies genetic variants associated with lentiform nucleus volume in Nâ€‰=â€‰1345 young and elderly subjects. Brain Imaging and Behavior, 2013, 7, 102-115.	2.1	26
277	Serum cholesterol and variant in cholesterol-related gene CETP predict white matter microstructure. Neurobiology of Aging, 2014, 35, 2504-2513.	3.1	26
278	Cortical Atrophy is Associated with Accelerated Cognitive Decline in Mild Cognitive Impairment with Subsyndromal Depression. American Journal of Geriatric Psychiatry, 2017, 25, 980-991.	1.2	26
279	Determination of renal molar concentrations of phosphorus-containing metabolitesin vivo using31P NMR. Magnetic Resonance in Medicine, 1987, 4, 244-251.	3.0	25
280	History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress. Drug and Alcohol Dependence, 2014, 142, 262-268.	3.2	25
281	Feature selection improves the accuracy of classifying Alzheimer disease using diffusion tensor images. , 2015, 2015, 126-130.		25
282	Volume of Home- and Community-Based Services and Time to Nursing-Home Placement. Medicare & Medicaid Research Review, 2012, 2, .	1.3	25
283	Quantifying anatomical shape variations in neurological disorders. Medical Image Analysis, 2014, 18, 616-633.	11.6	24
284	Effects of sex, race, ethnicity, and education on online aging research participation. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12028.	3.7	24
285	Predicting temporal lobe volume on MRI from genotypes using L¹-L² regularized regression. , 2012, , 1160-1163.		23
286	Multilocus genetic profiling to empower drug trials and predict brain atrophy. NeuroImage: Clinical, 2013, 2, 827-835.	2.7	23
287	Increased CNV-Region deletions in mild cognitive impairment (MCI) and Alzheimer's disease (AD) subjects in the ADNI sample. Genomics, 2013, 102, 112-122.	2.9	23
288	Mapping 3-year changes in gray matter and metabolism in AÎ²-positive nondemented subjects. Neurobiology of Aging, 2015, 36, 2913-2924.	3.1	23

#	Article	IF	Citations
289	Active Cigarette Smoking inÂCognitively-Normal Elders and Probable Alzheimerâ€™s Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers. Journal of Alzheimer's Disease, 2016, 54, 99-107.	2.6	23
290	Study partnerâ€reported decline identifies cognitive decline and dementia risk. Annals of Clinical and Translational Neurology, 2019, 6, 2448-2459.	3.7	23
291	Genomeâ€wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology. Alzheimer's and Dementia, 2020, 16, 1213-1223.	0.8	23
292	Dutch Brain Research Registry for study participant recruitment: Design and first results. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12132.	3.7	23
293	The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNIâ€3 updates and global perspectives. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12226.	3.7	23
294	Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3â€‰years. International Journal of Geriatric Psychiatry, 2012, 27, 355-363.	2.7	22
295	Empowering imaging biomarkers of Alzheimer's disease. Neurobiology of Aging, 2015, 36, S69-S80.	3.1	22
296	Genome-wide interaction analysis reveals replicated epistatic effects on brain structure. Neurobiology of Aging, 2015, 36, S151-S158.	3.1	22
297	Data-driven regions of interest for longitudinal change in frontotemporal lobar degeneration. NeuroImage: Clinical, 2016, 12, 332-340.	2.7	22
298	Dataâ€driven regions of interest for longitudinal change in three variants of frontotemporal lobar degeneration. Brain and Behavior, 2017, 7, e00675.	2.2	22
299	Dementia Risk in Posttraumatic Stress Disorder: the Relevance of Sleep-Related Abnormalities in Brain Structure, Amyloid, and Inflammation. Current Psychiatry Reports, 2017, 19, 89.	4.5	22
300	Use of computer simulations for quantitation of31P ISIS MRS results. NMR in Biomedicine, 1993, 6, 215-224.	2.8	21
301	Preserved Structural Network Organization Mediates Pathology Spread in Alzheimerâ€™s Disease Spectrum Despite Loss of White Matter Tract Integrity. Journal of Alzheimer's Disease, 2018, 65, 747-764.	2.6	21
302	A cognitive systems engineering design approach to improve the usability of electronic order forms for medical consultation. Journal of Biomedical Informatics, 2018, 85, 138-148.	4.3	21
303	Lower cerebral perfusion is associated with tau-PET in the entorhinal cortex across the Alzheimer's continuum. Neurobiology of Aging, 2021, 102, 111-118.	3.1	21
304	Are hippocampal size differences in posttraumatic stress disorder mediated by sleep pathology?. Alzheimer's and Dementia, 2014, 10, S146-54.	0.8	20
305	Effects of changing from non-accelerated to accelerated MRI for follow-up in brain atrophy measurement. NeuroImage, 2015, 107, 46-53.	4.2	20
306	Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimerâ€™s disease. BMC Medical Genomics, 2016, 9, 30.	1.5	20

#	Article	IF	Citations
307	Validation of online functional measures in cognitively impaired older adults. Alzheimer's and Dementia, 2020, 16, 1426-1437.	0.8	20
308	Hippocampal Surface Mapping of Genetic Risk Factors in AD via Sparse Learning Models. Lecture Notes in Computer Science, 2011, 14, 376-383.	1.3	20
309	Metabolic and nonmetabolic components of fatigue monitored with31P-NMR. Muscle and Nerve, 1994, 17, 1002-1009.	2.2	18
310	Small world network measures predict white matter degeneration in patients with early-stage mild cognitive impairment. , 2012, , 1405-1408.		18
311	Militaryâ€related risk factors for dementia. Alzheimer's and Dementia, 2018, 14, 1651-1662.	0.8	18
312	Algebraic Connectivity of Brain Networks Shows Patterns of Segregation Leading to Reduced Network Robustness in Alzheimerâ€™s Disease. Mathematics and Visualization, 2014, 2014, 55-64.	0.6	18
313	Mapping of cerebral metabolites in rats by1H magnetic resonance spectroscopic imaging. Distribution of metabolites in normal brain and postmortem changes. NMR in Biomedicine, 1993, 6, 311-317.	2.8	17
314	Alzheimer's Disease Neuroimaging Initiative special issue. Neurobiology of Aging, 2010, 31, 1259-1262.	3.1	17
315	AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials. Alzheimer's and Dementia, 2011, 7, e109-17.	0.8	17
316	Spectral graph theory and graph energy metrics show evidence for the alzheimer's disease disconnection syndrome in APOE-4 risk gene carriers. , 2015, 2015, 458-461.		17
317	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	2.7	17
318	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2022, 18, 1370-1382.	0.8	17
319	Effects of Baseline CSF Î±-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e85443.	2.5	16
320	Total Sleep Time Interacts With Age to Predict Cognitive Performance Among Adults. Journal of Clinical Sleep Medicine, 2018, 14, 1587-1594.	2.6	16
321	Using imputation to provide harmonized longitudinal measures of cognition across AIBL and ADNI. Scientific Reports, 2021, 11, 23788.	3.3	16
322	Metabolite1H relaxation in normal and hyponatremic brain. Magnetic Resonance in Medicine, 1996, 35, 688-696.	3.0	15
323	A critical appraisal of guidelines for electronic communication between patients and clinicians: the need to modernize current recommendations. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 413-418.	4.4	15
324	APOE Effect on Amyloid-Î² PET Spatial Distribution, Deposition Rate, and Cut-Points. Journal of Alzheimer's Disease, 2019, 69, 783-793.	2.6	15

#	Article	IF	Citations
325	Hoarding disorder is associated with self-reported cardiovascular / metabolic dysfunction, chronic pain, and sleep apnea. Journal of Psychiatric Research, 2021, 134, 15-21.	3.1	15
326	Assessing the reliability to detect cerebral hypometabolism in probable Alzheimer's disease and amnestic mild cognitive impairment. Journal of Neuroscience Methods, 2010, 192, 277-285.	2.5	14
327	Decreased Self-Appraisal Accuracy on Cognitive Tests of Executive Functioning Is a Predictor of Decline in Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2016, 8, 120.	3.4	14
328	Telomere Shortening in the Alzheimerâ€™s Disease Neuroimaging Initiative Cohort. Journal of Alzheimer's Disease, 2019, 71, 33-43.	2.6	14
329	Item response theory analysis of the Clinical Dementia Rating. Alzheimer's and Dementia, 2021, 17, 534-542.	0.8	14
330	The search for a convenient procedure to detect one of the earliest signs of Alzheimer's disease: A systematic review of the prediction of brain amyloid status. Alzheimer's and Dementia, 2021, 17, 866-887.	0.8	14
331	Latent Classes of Cognitive Functioning Among Depressed Older Adults Without Dementia. Journal of the International Neuropsychological Society, 2019, 25, 811-820.	1.8	13
332	Association of blood-based transcriptional risk scores with biomarkers for Alzheimer disease. Neurology: Genetics, 2020, 6, e517.	1.9	13
333	Internet-based hoarding assessment: The reliability and predictive validity of the internet-based Hoarding Rating Scale, Self-Report. Psychiatry Research, 2020, 294, 113505.	3.3	13
334	Traumatic brain injury and postâ€traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers. Alzheimer's and Dementia, 2023, 19, 884-895.	0.8	13
335	Factors which influence alterations of phosphates and pH in exercising human skeletal muscle: Measurement error, reproducibility, and effects of fasting, carbohydrate loading, and metabolic acidosis. Muscle and Nerve, 1995, 18, 60-67.	2.2	12
336	Alzheimer risk genes modulate the relationship between plasma apoE and cortical PiB binding. Neurology: Genetics, 2015, 1, e22.	1.9	12
337	Apolipoprotein Îµ4 Is Associated with Lower Brain Volume in Cognitively Normal Chinese but Not White Older Adults. PLoS ONE, 2015, 10, e0118338.	2.5	12
338	Seemingly unrelated regression empowers detection of network failure in dementia. Neurobiology of Aging, 2015, 36, S103-S112.	3.1	12
339	Amyloid in dementia associated with familial FTLD: not an innocent bystander. Neurocase, 2016, 22, 76-83.	0.6	12
340	Comparison of multi-sample variant calling methods for whole genome sequencing. , 2014, 2014, 59-62.		11
341	Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults. Neurobiology of Aging, 2019, 82, 110-119.	3.1	11
342	Effect of supranormal coronary blood flow on energy metabolism and systolic function of porcine left ventricle. Cardiovascular Research, 1992, 26, 1001-1006.	3.8	10

#	Article	IF	Citations
343	Does MRI scan acceleration affect power to track brain change?. Neurobiology of Aging, 2015, 36, S167-S177.	3.1	10
344	A T1 and DTI fused 3D corpus callosum analysis in MCI subjects with high and low cardiovascular risk profile. NeuroImage: Clinical, 2017, 14, 298-307.	2.7	10
345	Amyloid Associated Intermittent Network Disruptions in Cognitively Intact Older Subjects: Structural Connectivity Matters. Frontiers in Aging Neuroscience, 2017, 9, 418.	3.4	10
346	Comparative usability evaluation of consultation order templates in a simulated primary care environment. Applied Ergonomics, 2018, 73, 22-32.	3.1	10
347	A Graph-Based Integration of Multimodal Brain Imaging Data for the Detection of Early Mild Cognitive Impairment (E-MCI). Lecture Notes in Computer Science, 2013, 8159, 159-169.	1.3	10
348	Differences in Prefrontal, Limbic, and White Matter Lesion Volumes According to Cognitive Status in Elderly Patients with First-Onset Subsyndromal Depression. PLoS ONE, 2014, 9, e87747.	2.5	10
349	Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimer's and Dementia, 2022, 18, 2603-2613.	0.8	10
350	Self-reporting of psychiatric illness in an online patient registry is a good indicator of the existence of psychiatric illness. Journal of Psychiatric Research, 2022, 151, 34-41.	3.1	10
351	Brain atrophy rates in first degree relatives at risk for Alzheimer's. NeuroImage: Clinical, 2014, 6, 340-346.	2.7	9
352	The Impact of Amyloid Burden and APOE on Rates of Cognitive Impairment in Late Life Depression. Journal of Alzheimer's Disease, 2021, 80, 991-1002.	2.6	9
353	Exhaustive Search of the SNP-SNP Interactome Identifies Epistatic Effects on Brain Volume in Two Cohorts. Lecture Notes in Computer Science, 2013, 16, 600-607.	1.3	9
354	A Time Motion Study Evaluating the Impact of Geographic Cohorting of Hospitalists. Journal of Hospital Medicine, 2020, 15, 338-344.	1.4	9
355	Region-based analysis of rare genomic variants in whole-genome sequencing datasets reveal two novel Alzheimerâ€™s disease-associated genes: DTNB and DLG2. Molecular Psychiatry, 2022, 27, 1963-1969.	7.9	9
356	Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	9
357	Hypoglycemia prevents increase in lactic acidosis during reperfusion after temporary cerebral ischemia in rats. NMR in Biomedicine, 1995, 8, 171-178.	2.8	8
358	Multiple-echo proton spectroscopic imaging using time domain parametric spectral analysis. Magnetic Resonance in Medicine, 1998, 39, 528-538.	3.0	8
359	Cognitive Performance in Parkinsonâ€™s Disease in the Brain Health Registry. Journal of Alzheimer's Disease, 2019, 68, 1029-1038.	2.6	8
360	Reliability and Validity of a Home-Based Self-Administered Computerized Test of Learning and Memory Using Speech Recognition. Aging, Neuropsychology, and Cognition, 2022, 29, 867-881.	1.3	8

#	Article	IF	Citations
361	Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2. Journal of Alzheimer's Disease, 2021, 83, 915-925.	2.6	8
362	Commentary on â€œDiagnosis of Alzheimer's disease: Two decades of progress.â€•Central role of technology in the treatment and prevention of Alzheimer's disease. , 2005, 1, 112-113.		7
363	Implementing Models of Geriatric Careâ€”Behind the Scenes. Journal of the American Geriatrics Society, 2018, 66, 364-366.	2.6	7
364	Brain health registry GenePool study: A novel approach to online genetics research. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12118.	3.7	7
365	Health-related quality of life in hoarding: A comparison to chronic conditions with high disease burden. Journal of Psychiatric Research, 2022, 149, 68-75.	3.1	7
366	A single nucleotide polymorphism associated with reduced alcohol intake in the RASGRF2 gene predicts larger cortical volumes but faster longitudinal ventricular expansion in the elderly. Frontiers in Aging Neuroscience, 2013, 5, 93.	3.4	6
367	Evidence for ageâ€associated cognitive decline from Internet game scores. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 260-267.	2.4	6
368	Too Many Donâ€™ts and Not Enough Doâ€™s? A Survey of Hospitals About Their Portal Instructions for Patients. Journal of General Internal Medicine, 2020, 35, 1029-1034.	2.6	6
369	How Will Aducanumab Approval Impact AD Research?. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-2.	2.7	6
370	31P NMR studies of ATP concentrations andPiâ€“ATP exchange in the rat kidneyin Vivo: Effects of inhibiting and stimulating renal metabolism. Magnetic Resonance in Medicine, 1990, 14, 445-460.	3.0	5
371	Standing on the Shoulders of Giants: Improving Medical Image Segmentation via Bias Correction. Lecture Notes in Computer Science, 2010, 13, 105-112.	1.3	5
372	The ADNI Publication Policy: Commensurate recognition of critical contributors who are not authors. NeuroImage, 2012, 59, 4196-4200.	4.2	5
373	Editorial (Thematic Issue: Statistical Signal Processing in the Analysis, Characterization and Detection) Tj ETQq1 1 0.784314 rgBT /Ov	1.4	5
374	Head injury is associated with tau deposition on PET in MCI and AD patients. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12230.	2.4	5
375	Insecure messaging: how clinicians approach potentially problematic messages from patients. JAMIA Open, 2021, 3, 576-582.	2.0	5
376	Association between APOE Îµ2 and AÎ² burden in patients with Alzheimer- and vascular-type cognitive impairment. Neurology, 2020, 95, e2354-e2365.	1.1	4
377	A Randomized Trial of the Safety and Benefit of Transfusion Vs. Standard Care In the Prevention of Sickle Cell-Related Complications In Adults: a Preliminary Report From the Phase II NHLBI Comprehensive Sickle Cell Centers (CSCC) Study of Neuropsychological Dysfunction and Neuroimaging Abnormalities In Neurologically Intact Adult Patients with Sickle Cell Disease. Blood, 2010, 116, 3221-3221.	1.4	4
378	Magnetic Resonance Spectroscopy of the Brain in Alcohol Abuse. Alcohol Health and Research World, 1995, 19, 306-314.	0.2	4

#	Article	IF	Citations
379	â€œI Donâ€™t Want to Spend the Rest of my Life Only Going to a Gender Wellness Clinicâ€: Healthcare Experiences of Patients of a Comprehensive Transgender Clinic. Journal of General Internal Medicine, 2022, 37, 3396-3403.	2.6	4
380	Perspectives of general practitioners towards evaluation and treatment of cardiovascular diseases among older people. Journal of Primary Health Care, 2009, 1, 198-206.	0.6	4
381	Qualitative Analysis of Team Communication with a Clinical Texting System at a Midwestern Academic Hospital. Applied Clinical Informatics, 2022, 13, 391-397.	1.7	4
382	A single acquisition localization technique. Magnetic Resonance in Medicine, 1986, 3, 341-345.	3.0	3
383	MEDICARE EXPENDITURES FOR BENEFICIARIES WITH DEMENTIA OF THE ALZHEIMER'S TYPE. Journal of the American Geriatrics Society, 1999, 47, 1276-1276.	2.6	3
384	Improving Comprehension of Medication Instructions in Older Adults with Heart Failure: A Patient-Centered Approach. Proceedings of the Human Factors and Ergonomics Society, 2003, 47, 232-236.	0.3	3
385	Refining Mild-to-Moderate Alzheimer Disease Screening: A Tool for Clinicians. Journal of the American Medical Directors Association, 2016, 17, 913-920.	2.5	3
386	[P2â€“052]: THE DUTCH BRAIN HEALTH REGISTRY: OPTIMIZING RECRUITMENT FOR DEMENTIA RESEARCH. Alzheimer's and Dementia, 2017, 13, P624.	0.8	3
387	Lessons and Outcomes of Mobile Acute Care for Elders Consultation in a Veterans Affairs Medical Center. Journal of the American Geriatrics Society, 2019, 67, 818-824.	2.6	3
388	Machine learning approaches to predicting amyloid status using data from an online research and recruitment registry: The Brain Health Registry. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12207.	2.4	3
389	Remote blood collection from older adults in the Brain Health Registry for plasma biomarker and genetic analysis. Alzheimer's and Dementia, 2022, , .	0.8	3
390	Proton and Phosphorus NMR Studies of Traumatic Brain Injury in Rats. Annals of the New York Academy of Sciences, 1987, 508, 497-500.	3.8	2
391	Preface. Alzheimer's and Dementia, 2014, 10, S92-3.	0.8	2
392	Medication management interventions in patients enrolled in GRACE Team Care. Geriatric Nursing, 2016, 37, 371-375.	1.9	2
393	Preadmission antidepressant use and bladder cancer: a population-based cohort study of stage at diagnosis, time to surgery, and surgical outcomes. BMC Cancer, 2018, 18, 1035.	2.6	2
394	Letter to the Author, concerning the publication: Amyloid pathology fingerprint differentiates post-traumatic stress disorder and traumatic brain injury. Mohamed AZ, et al. Neuroimaging Clinical 2018 Jun 5;19:716â€“726. NeuroImage: Clinical, 2019, 23, 101868.	2.7	2
395	Predicting amyloid status using selfâ€report information from an online research and recruitment registry: The Brain Health Registry. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12102.	2.4	2
396	Poor Sleep Quality and Daytime Fatigue Are Associated With Subjective but Not Objective Cognitive Functioning in Clinically Relevant Hoarding. Biological Psychiatry Global Open Science, 2022, 2, 480-488.	2.2	2

#	Article	IF	Citations
397	Towards Constructing a New Taxonomy for Psychiatry Using Self-reported Symptoms. Studies in Health Technology and Informatics, 2015, 216, 736-40.	0.3	2
398	Diffusion tensor distribution function metrics boost power to detect deficits in Alzheimer's disease. , 2016, , .		1
399	P1â€602: DUTCH ONLINE REGISTRY FOR RECRUITMENT OF PARTICIPANTS FOR DEMENTIA STUDIES: HERSENONDERZOEK.NL AND BRAIN HEALTH REGISTRY. Alzheimer's and Dementia, 2018, 14, P569.	0.8	1
400	A National County-Level Assessment of U.S. Nursing Facility Characteristics Associated with Long-Term Exposure to Traffic Pollution in Older Adults. International Journal of Environmental Research and Public Health, 2018, 15, 487.	2.6	1
401	Nursing Home Residents With Urinary Tract Infections: A Comparison of Treatment in Place vs Hospitalization. Journal of the American Medical Directors Association, 2021, 22, 2603-2605.	2.5	1
402	Leon Thal's vision for the treatment and prevention of Alzheimer's disease. , 2008, 4, S150-S152.		0
403	Joint Independent Component Analysis of Brain Perfusion and Structural Magnetic Resonance Images in Dementia. , 2010, , .		0
404	Commentary on â€œBiomarkers in Alzheimer's disease drug development.â€•The view from Alzheimer's Disease Neuroimaging Initiative. , 2011, 7, e45-e47.		0
405	Phantom-based MRI corrections and power to track brain change. , 2012, , .		0
406	P4-318: EVIDENCE FOR AGE-ASSOCIATED COGNITIVE DECLINE IN A LARGE DATABASE OF LUMOSITY INTERNET GAME SCORES. , 2014, 10, P902-P903.		0
407	P4-317: BRAINHEALTHREGISTRY.ORG: AN ONLINE REGISTRY FOR NEUROSCIENCE CLINICAL TRIALS-PRELIMINARY RESULTS OF UNSUPERVISED ONLINE NEUROPSYCHOLOGICAL TESTING. , 2014, 10, P902-P902.		0
408	P1-318: Internet-based recruitment and screening of subjects for ad trials using longitudinal data from the brain health registry. , 2015, 11, P478-P479.		0
409	P4-396: Using an Internet Registry to Supplement Recruitment Efforts for Clinical Research. , 2016, 12, P1189-P1189.		0
410	[P3â€“032]: SSRI USE ASSOCIATED WITH REDUCED AMYLOID BURDEN IN PERSONS WITH COMBATâ€RELATED PTSD: PRELIMINARY FINDINGS FROM ADNIâ€DOD. Alzheimer's and Dementia, 2017, 13, P942.	0.8	0
411	[P4â€“203]: THE ALZHEIMER's DISEASE PATIENTâ€•AND CAREGIVERâ€POWERED RESEARCH NETWORK: A PATIENTâ€• AND CAREGIVERâ€CENTERED INITIATIVE TO FACILITATE ALZHEIMER's CLINICAL RESEARCH. Alzheimer's and Dementia, 2017, 13, P1342.	0.8	0
412	[ICâ€Pâ€041]: SAMPLE SIZES FOR 24â€MONTH ALZHEIMER's PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOIDâ€POSITIVE ADULTS. Alzheimer's and Dementia, 2017, 13, P36.	0.8	0
413	[ICâ€Pâ€209]: CAVEATS WHEN SUBTRACTING TWO SERIAL MEASUREMENTS TO ESTIMATE THE NUMBER OF PARTICIPANTS NEEDED FOR CLINICAL TRIALS THAT ARE LONGER OR SHORTER THAN THE OBSERVED MEASUREMENT INTERVAL. Alzheimer's and Dementia, 2017, 13, P151.	0.8	0
414	[P2â€“333]: CAVEATS WHEN SUBTRACTING TWO SERIAL MEASUREMENTS TO ESTIMATE THE NUMBER OF PARTICIPANTS NEEDED FOR CLINICAL TRIALS THAT ARE LONGER OR SHORTER THAN THE OBSERVED MEASUREMENT INTERVAL. Alzheimer's and Dementia, 2017, 13, P748.	0.8	0

#	Article	IF	Citations
415	[P4â€“421]: ELEVATED PLASMA NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH REDUCED GREY MATTER DENSITY IN AD AND MCI. Alzheimer's and Dementia, 2017, 13, P1493.	0.8	0
416	Response to Zywieck and Kirkby paper. Neurobiology of Aging, 2018, 69, 298-299.	3.1	0
417	3220 Can you read me now? Clinician variations in managing and responding to secure messages from patients. Journal of Clinical and Translational Science, 2019, 3, 59-59.	0.6	0
418	S4â€01â€01: IDENTIFYING ELDERS AT RISK FOR COGNITIVE DECLINE USING THE BRAIN HEALTH REGISTRY (BHR). Alzheimer's and Dementia, 2019, 15, P1215.	0.8	0